Kaplan-Meier Statistics to Estimate Treatment Success: Response

. 2023 Dec 1;43(4):e361-e362.

doi: 10.1097/WNO.0000000000001628. Epub 2022 May 24.

Affiliations

¹ Santhera Pharmaceuticals, Pratteln, Switzerland , Santhera Pharmaceuticals, Pratteln, Switzerland, Department of Neurology, Friedrich-Baur-Institute, University Hospital of the Ludwig-Maximilians-University, Munich, Germany, German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; and Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.

Magda Silva et al. J Neuroophthalmol. 2023.

. 2023 Dec 1;43(4):e361-e362.

doi: 10.1097/WNO.0000000000001628. Epub 2022 May 24.

¹ Santhera Pharmaceuticals, Pratteln, Switzerland , Santhera Pharmaceuticals, Pratteln, Switzerland, Department of Neurology, Friedrich-Baur-Institute, University Hospital of the Ludwig-Maximilians-University, Munich, Germany, German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; and Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.

No abstract available

References

1. Catarino C, von Livonius B, Priglinger C, Banik R, Matloob S, Tamhankar MA, Castillo L, Friedburg C, Halfpenny CA, Lincoln JA, Traber GL, Acaroglu G, Black GCM, Doncel C, Fraser CL, Jakubaszko J, Landau K, Langenegger SJ, Muñoz-Negrete FJ, Newman NJ, Poulton J, Scoppettuolo E, Subramanian P, Toosy AT, Vidal M, Vincent AL, Votruba M, Zarowski M, Zermansky A, Lob F, Rudolph G, Mikazans O, Silva M, Llòria X, Metz G, Klopstock T. Real-world clinical experience with idebenone in the treatment of leber hereditary optic neuropathy. J Neuroophthalmol. 2020;40:558–565.